HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine.
HPV16-E711-20 epitope is a synthetic peptide derived from the E7 protein of Human Papillomavirus type 16, a high-risk HPV subtype extensively studied in the context of viral oncogenesis and immunological research. This peptide represents a well-characterized sequence commonly used as a model antigen for investigating T cell responses, antigen processing, and immune recognition related to HPV-associated malignancies. Its defined amino acid sequence and immunodominant properties make it a valuable tool for dissecting cellular mechanisms underlying viral persistence, immune evasion, and the development of virus-driven cancers in preclinical and translational research settings.
Immunological assay development: As a prototypical T cell epitope, the HPV16-E711-20 peptide is widely utilized in the development and validation of immunological assays, such as ELISpot, intracellular cytokine staining, and tetramer-based flow cytometry. These assays enable precise quantification and characterization of antigen-specific CD8+ cytotoxic T lymphocyte responses in experimental models and ex vivo human samples. By providing a consistent and well-defined target, the peptide supports standardized assessment of immune reactivity, facilitating comparative studies and method optimization across laboratories.
Cellular immunity studies: The E7-derived epitope is instrumental in exploring the mechanisms of antigen processing, presentation, and T cell activation within the context of HPV infection. Researchers employ this peptide to stimulate peripheral blood mononuclear cells or established T cell lines, allowing for detailed analysis of MHC class I-restricted recognition, effector function, and memory formation. These investigations yield insights into the immunodominance hierarchy, cross-presentation pathways, and the influence of viral antigens on host immune surveillance.
Vaccine research and evaluation: The HPV16-E711-20 peptide serves as a benchmark antigen in preclinical vaccine studies aimed at eliciting robust cellular immune responses against HPV-driven tumors. Its inclusion in peptide pools or as a single epitope enables assessment of vaccine-induced CD8+ T cell activity, supporting the optimization of vaccine formulations and adjuvant combinations. The peptide's relevance to HPV16-associated malignancies makes it a critical component in evaluating the immunogenicity and efficacy of novel immunoprophylactic and immunotherapeutic strategies in animal models and in vitro systems.
Epitope mapping and antigen discovery: Researchers leverage the defined sequence of this epitope to delineate T cell receptor specificity, map fine epitope regions within the E7 protein, and identify cross-reactive determinants among HPV variants. Such studies contribute to a deeper understanding of antigenic structure-function relationships, inform the design of next-generation peptide vaccines, and support the identification of novel targets for immunotherapy. The peptide's use in high-throughput screening platforms accelerates the discovery of immunologically relevant epitopes and the characterization of their interaction with HLA molecules.
Adoptive cell therapy research: The HPV16-E711-20 peptide is frequently employed to expand and functionally characterize HPV-specific T cell populations for adoptive transfer protocols in experimental models. By providing a defined stimulus for in vitro priming and expansion, the peptide enables selection and quality control of antigen-specific T cells, which are subsequently evaluated for cytotoxicity, persistence, and anti-tumor activity. These applications support the advancement of adoptive immunotherapy approaches targeting virally induced neoplasms, contributing to the broader field of personalized cancer immunotherapy research.
2. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
3. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More